NCT02789605View on ClinicalTrials.gov

Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 4, 2018

Primary Completion Date

November 25, 2019

Study Completion Date

July 15, 2020

Conditions
Aphthous Stomatitis
Interventions
DRUG

Bacilor

Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.

DRUG

Placebo

Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.

Trial Locations (1)

06200

CHU de NIce - Dermatologie, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT02789605 - Effectiveness and Safety of Lactobacillus Rhamnosus Lcr35® in the Treatment of Recurrent Aphthous Stomatitis | Biotech Hunter | Biotech Hunter